Anton Klingler - Concepedia

Author

Anton Klingler

Vienna Biocenter

Also Known As

A Klingler, Anton Klingler, Klingler, Anton

Publications

594

Citations

H-Index

Concepts

All Affiliations

Vienna Biocenter Medical University of Vienna Valneva (Austria)Intercell (Austria)Ghent University Hospital

About

Anton Klingler is an author at Vienna Biocenter specializing in medicine, vaccination, and vaccine development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	431
2	Immunology	5	5	406
3	Vaccine Development	5	5	406
4	Precision Vaccinology	2	2	135
5	Epidemiology	1	1	25

Anton Klingler

Publications

594

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial Erich Tauber, Herwig Kollaritsch, Maria Korinek, The Lancet VaccinologyVaccine SafetyVaccinationVaccine DevelopmentPhase Iii	2007	192
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial Nina Wressnigg, Romana Hochreiter, Oliver Zoihsl, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyVaccine DevelopmentMedicine	2020	98
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial Christopher Adlbrecht, Raphael Wurm, Pieter Depuydt, Critical Care	2020	76
A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients Jordi Rello, Krenn Claus-Georg, Gottfried J. Locker, Critical Care	2017	75
Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO® Elisabeth Schuller, Anton Klingler, Katrin Dubischar-Kastner, Vaccine VaccinationVaccine SafetyVaccine Ixiaro®Vaccine DevelopmentImmunology	2011	46
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults Nicole Bézay, Romana Hochreiter, Vera Kadlecek, The Lancet Infectious Diseases VaccinationVaccine DevelopmentVaccine ResearchMedicineImmunology	2023	37
Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up Katrin Dubischar-Kastner, Astrid Kaltenboeck, Anton Klingler, Vaccine VaccinationVaccine SafetyVaccine DevelopmentJapanese Encephalitis VaccineImmunology	2010	33
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies Nicole Bézay, Laura Danielle Wagner, Vera Kadlecek, The Lancet Infectious Diseases VaccinationVaccine SafetyDose LevelVaccination ScheduleVaccine Efficacy	2024	25
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial Santhosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, The Lancet Infectious Diseases	2024	12

Page 1